Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $60.22.

A number of brokerages have commented on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, December 19th. Finally, UBS Group initiated coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price target on the stock.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Creative Planning purchased a new position in shares of Celldex Therapeutics during the 3rd quarter valued at approximately $504,000. Values First Advisors Inc. increased its holdings in Celldex Therapeutics by 13.4% in the third quarter. Values First Advisors Inc. now owns 24,172 shares of the biopharmaceutical company’s stock valued at $822,000 after buying an additional 2,853 shares in the last quarter. Novo Holdings A S increased its holdings in Celldex Therapeutics by 13.4% in the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after buying an additional 113,663 shares in the last quarter. Emerald Mutual Fund Advisers Trust raised its position in shares of Celldex Therapeutics by 92.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 243,795 shares of the biopharmaceutical company’s stock worth $8,287,000 after acquiring an additional 116,832 shares during the period. Finally, Emerald Advisers LLC boosted its stake in shares of Celldex Therapeutics by 129.9% during the 3rd quarter. Emerald Advisers LLC now owns 456,202 shares of the biopharmaceutical company’s stock worth $15,506,000 after acquiring an additional 257,773 shares in the last quarter.

Celldex Therapeutics Trading Down 2.0 %

NASDAQ:CLDX opened at $22.59 on Friday. The company has a market capitalization of $1.50 billion, a P/E ratio of -8.79 and a beta of 1.60. Celldex Therapeutics has a 12 month low of $20.91 and a 12 month high of $53.18. The firm has a fifty day simple moving average of $24.47 and a 200-day simple moving average of $29.49.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.